BioSpace News Archive

Abiomed, Inc., a leading provider of breakthrough heart support technologies, announced that it will host a Virtual Investor Day covering Clinical Data & Innovation on May 27, 2020 from 8:30 a.m. – 12:00 p.m. EDT.

Surface Oncology announced that it has raised gross proceeds of approximately $28.9 million through its At-the-Market, or ATM, facility with participation based on interest received from EcoR1 Capital LLC, Venrock Healthcare Capital Partners, BVF Partners L.P., and RS Investments, a Victory Capital investment franchise.

KindredBio Selected as Second Contract Manufacturing Organization GMP Production for Phase 1 Study Initiated

Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine candidate for COVID-19.

Centene Corporation announced today it has engaged with local providers and community partners to support District of Columbia residents in response to the COVID-19 pandemic. The Company will donate over 75,000 pieces of personal protective equipment (PPE) to Washington D.C. providers to enable them to meet the urgent needs of patients,

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the launch of its new JOURNEY II Unicompartmental Knee (UK) System

Peptide Prevents Spike Protein Binding and Slows the Transmission of COVID-19 Technology and intellectual property is licensed exclusively from Virginia Commonwealth University and invented by Michael H. Peters, Ph.D. [20-May-2020] NEW YORK , May 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced lic

Randomized, double-blind clinical study will test Hydroxychloroquine as a prophylactic treatment to prevent high-risk healthcare workers from contracting COVID-19 DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--( BUSINESS WIRE )-- IQVIA™ (NYSE: IQV) today announced that the Walter and Eliza Hall Institute of Medical Research , a leading biomedical research organization in Australia, has selected IQVIA to manage COVID SHIELD, a Phase II/III randomize

Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol ® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1) Top line results of Phase I study confirm favorable safety and tolerability of Trappsol ® Cyclo™ in patients with NPC1 and demonstrate biological responses for both dose groups. An Unblinded Interim Analysis of Phase I/II study shows encourag

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the pricing of its public offering of 2,758,620 units at a price to the public of $7.25 per